SRNEQ Stock Price, News & Analysis

Sorrento Therapeutics, Inc. (SRNEQ) is an antibody-centric, clinical-stage biopharmaceutical company striving to develop innovative therapies for cancer, inflammation, and autoimmune diseases. The company's primary focus lies in developing late-stage biosimilar and biobetter antibodies, along with clinical car-t therapies targeting solid tumors.

Sorrento is deeply dedicated to creating life-saving therapeutics to enhance patient outcomes. Their approach includes a diverse range of immuno-oncology platforms and assets like next-generation tyrosine kinase inhibitors, fully human antibodies, immuno-cellular therapies, antibody-drug conjugates, and oncolytic viruses. Additionally, Sorrento is actively working on antiviral therapies, vaccines against coronaviruses, and diagnostic solutions to combat critical diseases.

The company's commitment extends to developing innovative treatments for various medical conditions, such as advanced pain management offerings and solutions for cancer and autoimmune diseases. Sorrento has a rich pipeline of promising products under development, including novel pain management formulations, non-opioid treatments, and treatments for postherpetic neuralgia.

With a robust portfolio and a visionary approach to healthcare, Sorrento Therapeutics, Inc. stands at the forefront of cutting-edge biopharmaceutical research and development.